- Home
- »
- Biotechnology
- »
-
Small-scale Bioreactors Market Size & Share Report, 2033GVR Report cover
Small-scale Bioreactors Market (2026 - 2033)
Size, Share & Trends Analysis Report By Product (Reusable Bioreactors, Single-use Bioreactors), By Capacity (5 ML-100 ML, 100 ML-250 ML, 250 ML-500 ML), By Application, By End-user, By Region, And Segment Forecasts
Market Size, 2025
$826.6MMarket Estimate, 2026
$877.8MMarket Forecast, 2033
$1,497.2MCAGR, 2026–2033
7.9%Small-scale Bioreactors Market Summary
The global small-scale bioreactors market was valued at USD 826.6 million in 2025 and and is projected to grow from USD 877.8 million to USD 1,497.2 million by 2033, at a CAGR of 7.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.3% in 2025. This growth is primarily driven by the increasing use of small-scale bioreactors in the pharmaceutical industry and continuous portfolio expansion by major industry players.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
Key Market Trends & Insights
- By product: Single-use bioreactors segment dominated the market, with a revenue share of 55.0% in 2025.
- By capacity: 1L-3L segment held the largest market share of 26.2% in 2025.
- By application: process development segment accounted for the largest revenue share of 35.0% in 2025.
- By end user: Pharmaceutical & biopharmaceutical companies segment held the largest revenue share of 42.8% in 2025.
Regional Highlights
- Largest regional market: North America (37.3% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 826.6 Million
- Estimated market size in 2026: USD 877.8 Million
- Projected market size by 2033: USD 1,497.2 Million
- CAGR (2026-2033): 7.9%
Prism AI by Grand View Research Free to tryAsk a question about the small-scale bioreactors marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →Small-scale bioreactors are critical in process development and optimization, making them essential in modern bioproduction and research workflows.
To learn more about this report,Download Free Sample Report
Market Dynamics
The rapid expansion of the biopharmaceutical industry has significantly boosted the demand for small-scale bioreactors. For instance, in June 2025, Belgian early-stage investor Biotope raised funding to support up to 30 international biotech startups, strengthening its commitment to fostering innovation across the European biotechnology sector. This trend highlights the expanding ecosystem and continued growth potential for small-scale bioreactor technologies worldwide. As companies focus on developing innovative biologics such as monoclonal antibodies, vaccines, and gene therapies, small-scale bioreactors precisely control critical parameters like temperature, pH, and oxygen levels, enabling efficient early-stage research and process development. Their flexibility, cost-effectiveness, and ability to support high-throughput screening make them essential tools for preclinical trials, small-batch production, and process optimization, helping streamline scale-up to commercial manufacturing.
Latest Biotechnology Funding,2025
Date
Company
Technology
Therapeutic area
11-Jun-25
SpliceBio
Gene therapy
Ophthalmology, Genetic and Genomic Medicine
9-Jun-25
Mosanna Therapeutics
Small molecules
Psychiatry
6-Jun-25
Citius Pharmaceuticals
Fusion protein
Oncology
5-Jun-25
Kelun-Biotech
Small molecules
Oncology
5-Jun-25
QureBio
Bispecific antibody
Oncology
4-Jun-25
Merus
Bispecific antibody
Oncology
4-Jun-25
Alvotech
Monoclonal antibody
Inflammatory Diseases
13-May-25
TILT Biotherapeutics
Oncolytic virus
Oncology
12-May-25
Abeona Therapeutics
Cell therapies, Gene therapy
Rare Diseases (Orphan Diseases)
8-May-25
HAYA Therapeutics
Genomics
Cardiovascular Diseases, Pulmonology
7-May-25
ImmuneWalk Therapeutics
Monoclonal antibody
Inflammatory Diseases
6-May-25
Nuevocor
Gene therapy
Cardiovascular Diseases
Source: Labiotech, Secondary Research, Grand View Research
Moreover, growing investment in biotechnology education and academic research drives the adoption of small-scale bioreactors in universities and research institutes worldwide. These systems offer a compact, affordable, and versatile platform ideal for hands-on training, prototype development, and a wide range of bioprocess experiments, even in budget-constrained environments. The ability to conduct parallel experiments and quickly adjust process parameters enhances research flexibility and innovation, making small-scale bioreactors indispensable for advancing scientific knowledge and supporting the next generation of biotechnologists.
The high initial investment required for advanced small-scale bioreactors can restrain market growth, particularly among startups, smaller biotechnology companies, and academic research institutes. Automated systems equipped with integrated sensors, process-control software, and parallel processing capabilities often require additional expenditure on installation, calibration, maintenance, and operator training. These costs can limit equipment procurement among budget-constrained end users and delay the adoption of advanced systems for process development, screening, and optimization.
For instance, in October 2024, Univercells Technologies, part of Donaldson, launched the scale-X nexo mini bioreactor for cell culture process development. The system was designed to reduce media and reagent consumption and offered up to a 60% reduction in cost per run compared with other entry-level fixed-bed bioreactors. The launch highlights the importance of cost efficiency in small-scale bioprocessing and the need to manage operating expenses alongside equipment investment.
Advancements in automated small-scale bioreactor platforms
Advancements in small-scale bioreactor technologies are creating opportunities in the market by improving process reproducibility, automation, and scalability. The development of miniaturized systems, single-use technologies, and real-time monitoring capabilities is enabling efficient process optimization while reducing resource consumption and operational complexity. These innovations support the demand for flexible and cost-effective bioreactor systems across pharmaceutical research, cell culture, and microbial fermentation.
For instance, in September 2026, Infors AG launched the Multifors 3 benchtop bioreactor platform, which supports working volumes from 100 mL to 10 L and both cell culture and microbial fermentation. The system automatically records process parameters, sensor metadata, and hardware configurations, helping researchers reproduce experimental conditions and streamline technology transfer. Its compatibility with glass and single-use vessels also provides flexibility across laboratory workflows, supporting demand for advanced small-scale bioprocess development systems.
Market Concentration & Characteristics
The degree of innovation in the small-scale bioreactors industry is significant. Innovations such as enhanced automation, real-time sensor integration, and digital process control enable precise monitoring and optimization of culture conditions, improving reproducibility and efficiency. For instance, in October 2024, Univercells Technologies by Donaldson launched the scale-X nexo bioreactor in Belgium. This miniaturized, fixed-bed bioreactor features a 0.5 m² growth surface to streamline cell culture process development across various modalities. The scale-X nexo bioreactor reduces process development timelines and costs, providing a cost-effective solution for early-stage development and making these innovative small-scale systems indispensable for accelerating biopharmaceutical development and research.
Increasing mergers and acquisitions within the biotech and biopharma industries stimulate demand for small-scale bioreactors by consolidating R&D efforts and expanding product pipelines. For instance, in December 2022, MilliporeSigma acquired Erbi Biosystems, enhancing its upstream portfolio with Breez micro-bioreactor technology to accelerate scalability, automated continuous bioprocessing. Such consolidations often require flexible, scalable bioprocessing platforms to harmonize workflows, optimize process development, and manage multiple parallel projects efficiently. Integrating newly acquired technologies also drives companies to invest in adaptable small-scale systems that support innovation and operational synergy.
To learn more about this report,Download Free Sample Report
Stringent regulatory requirements imposed by global agencies compel biopharmaceutical companies to adopt small-scale bioreactors for precise process control and validation during early-stage development. These systems help ensure consistent, reproducible results that comply with quality and safety standards, reducing risks during scale-up and facilitating smoother regulatory approvals. Enhanced real-time monitoring features in modern bioreactors align with evolving guidelines, further increasing their adoption.
Manufacturers' continuous efforts to expand and innovate their small-scale bioreactor product lines drive market growth by offering advanced features like modular designs, single-use compatibility, and automation. For instance, in January 2025, Biosphere, a California-based startup, unveiled a UV-sterilized bioreactor to reduce biomanufacturing costs. The company secured USD 8.8 million in seed funding and a USD 1.5 million U.S. Department of Defense contract to scale its technology. By replacing traditional steam-based sterilization with UV light, Biosphere's system aims to lower capital expenditures and simplify bioreactor design, potentially enhancing the scalability of bioproduction processes. These product enhancements improve usability, scalability, and application range from microbial fermentation to complex mammalian cell cultures, making small-scale bioreactors more attractive to a wider user base, including startups, research institutes, and biopharmaceutical firms.
The growth of biotechnology hubs and increasing investments in emerging markets, particularly in Asia-Pacific and Latin America, contribute to the regional expansion of the small-scale bioreactors industry. Rising government funding for biotech research, improved infrastructure, and growing local startups fuel demand in these regions. This geographic diversification broadens market opportunities and drives global adoption of small-scale bioreactor technologies.
Product Insights
The single-use bioreactors segment dominated the industry with a revenue share of 55.0% in 2025 and is also expected to register the fastest growth rate during the forecast period, as these have recently been used more frequently in novel biotech processes. For instance, in March 2022, Cellexus International, based in Dundee, UK, introduced the CellMaker single-use airlift bioreactor. This system utilizes gas percolation for gentle mixing, reducing shear stress on delicate cell cultures. The bioreactor's disposable bags eliminate the need for sterilization, cutting downtime, and chemical use. This is mainly due to their exceptional ability to improve flexibility, lower investment, and reduce operational expenses. Such advantages of single-use products over other small-scale bioreactors are expected to drive segment growth.
The reusable bioreactors are estimated to register a significant growth rate during the forecast period. There is a higher need for reusable bioreactors in the pharmaceutical and biopharmaceutical industries because they can produce larger quantities of products. Due to its rigid design, the reusable bioreactor has several other benefits, such as low costs, a long lifespan, flexible accessory configuration, and simple handling.
Capacity Insights
The 1L-3L capacity segment held the largest market share of 26.4% in 2025.The segment is projected to expand further at the fastest growth rate, retaining its dominant position throughout the forecast period. This is due to the wide-scale availability of bioreactors with a working volume capacity of 1L-3L. Due to the advantages of these laboratory systems, most key players also offer these products and contribute to the expansion of the small-scale reactor industry.
The 100-250 mL capacity segment is anticipated to register the fastest CAGR during the forecast period, driven by increasing adoption of small-scale bioreactors for high-throughput screening, cell line evaluation, and process optimization. Their ability to support parallel experiments while minimizing media and reagent consumption is expected to drive demand among pharmaceutical companies, CROs, and academic research institutions.
Application Insights
The process development segment dominated the market with a revenue share of 35.0% in 2025, driven by the increasing use of these systems to optimize cell culture conditions, evaluate media formulations, and establish scalable bioprocesses. Growing investments in biologics and advanced therapeutics are further supporting demand for small-scale bioreactors during early-stage process development.
The screening segment is anticipated to register the fastest CAGR during the forecast period, driven by increasing demand for high-throughput screening of cell lines, media formulations, and process parameters. Growing adoption of parallel bioreactor systems to accelerate early-stage research and optimize bioprocess conditions is further expected to support segment growth.
End User Insights
The pharmaceutical & biopharmaceutical companies dominated the market, with a revenue share of 42.8% in 2025, driven by increasing investments in biologics development, process optimization, and cell culture research. Growing adoption of small-scale bioreactors for early-stage drug development, process characterization, and scale-up studies further contributed to segment dominance.
To learn more about this report,Download Free Sample Report
The CROs & CMOs segment is anticipated to register the fastest CAGR during the forecast period. CMOs and CROs constantly search for improved single-use systems for their clients to improve their service offerings. These companies have adopted novel single-use bioreactors much more quickly than therapeutic manufacturers. CMOs and CROs remain competitive when they create biologics more successfully and affordably, especially for R&D and clinical trials.
Regional Insights
North America dominated the small-scale bioreactors industry in 2025 with a share of 37.3% owing to key players in manufacturing advanced small-scale and single-use bioreactors. The rising investments in biopharmaceutical research, owing to the growing incidences of chronic disease & increased demand for novel biologic drugs as well as advanced equipment, including small-scale bioreactors, will drive the industry growth. For instance, In January 2022, Erbi Biosystems, based in Cambridge, Massachusetts, secured USD 4 million in funding to advance its Breez micro-bioreactor platform. The Breez system offers online sensing and control of pH, cell density, dissolved oxygen, and CO₂, facilitating sophisticated feeding strategies and media exchanges. Its compact design and high-performance capabilities make it suitable for cell therapy development and GMP manufacturing applications, further deriving demand in the small-scale bioreactors industry.
To learn more about this report,Download Free Sample Report
U.S Small-scale Bioreactors Market Trends
The small-scale bioreactors market in the U.S. is expected to grow over the forecast period, benefiting from extensive biotech research funding, a large network of academic and clinical research centers, and a thriving biopharmaceutical industry. Ongoing advancements in cell culture, fermentation, and regenerative medicine drive the demand for customizable and scalable bioreactor solutions.
Europe Small-scale Bioreactors Market Trends
Europe is a significant market for small-scale bioreactors, with countries like the UK and Germany leading due to their advanced biotech industries and robust research infrastructure. Increased funding for life sciences education and startups, coupled with strong collaborations between academia and industry, supports the growing adoption of bioreactor technologies. The region’s focus on sustainable bioprocessing also encourages innovation in bioreactor design and applications.
The small-scale bioreactors industry in the UK held a significant share in 2025. The UK’s well-established life sciences sector and government-backed innovation programs foster a strong market for small-scale bioreactors. For instance, in April 2025, Project Nexus, a UK-based collaboration, launched to develop sustainable 3D-printed micro bioreactors using bio-based resins. The initiative aims to reduce plastic waste in biopharmaceutical manufacturing. Partners include Photocentric, Sartorius, Metamorphic, CPI, the University of Sheffield, and Imperial College London. Moreover, The country’s focus on personalized medicine and bioprocess optimization has led to increased adoption of advanced bioreactor systems in academic and industrial research.
Germany’s strong industrial biotechnology sector, supported by world-class research institutions, propels demand for small-scale bioreactors. Emphasis on sustainable manufacturing and bio-based products has spurred innovation in bioreactor technologies tailored to various bioprocesses.
Asia Pacific Small-scale Bioreactors Market Trends
Asia Pacific is expected to register the fastest CAGR of 8.5% during the forecast period because it is home to some of the world's most rapidly expanding biotechnological industries and economies. For instance, in June 2024, researchers from the Singapore-MIT Alliance for Research and Technology (SMART) developed a high-density microfluidic bioreactor for CAR T-cell production. This 2 mL automated closed-system chip enables efficient, scalable manufacturing with reduced reagent use and shorter production times, potentially facilitating point-of-care applications. Such innovations, combined with increasing government support and investment in biotechnology infrastructure, are expected to drive robust growth and widespread adoption of small-scale bioreactor technologies across the region.
The small-scale bioreactors market in China is expected to grow over the forecast period, owing to the country’s rapidly growing biotechnology industry, supported by extensive government initiatives and increasing R&D expenditure, fuels market growth for small-scale bioreactors. The country’s expanding biopharmaceutical manufacturing capabilities and startup ecosystem further boost adoption.
The Japan small-scale bioreactors market is witnessing significant growth over the forecast period owing to key market players' investments in biotechnology and pharmaceutical research. For instance, in January 2024, AGC Biologics announced a new 20,000 m² cell therapy facility in Yokohama, Japan, set to operate by 2026 with single-use bioreactors. Such strategic investments underscore the growing demand for small-scale bioreactors in Japan, driven by the country's focus on innovation in biopharmaceutical development and regenerative medicine.
Latin America Small-scale Bioreactors Market Trends
The Latin America small-scale bioreactors market is driven by increasing investments in biopharmaceutical research, expanding biologics manufacturing capabilities, and growing adoption of advanced cell culture technologies. Rising demand for monoclonal antibodies, vaccines, and cell and gene therapies, particularly in Brazil and Mexico, is further supporting regional market growth.
MEA Small-scale Bioreactors Market Trends
The MEA market for small-scale bioreactors is in the early stages of development, driven by rising investments in biotechnology infrastructure and research activities. While the market is still evolving relative to more established regions, increasing government initiatives and growing public and private sector interest are anticipated to accelerate adoption and open up promising opportunities in the future.
Key Small-scale Bioreactors Company Insights
The global small-scale bioreactors market is highly competitive, with key players accounting for most of the market share. Companies involved in the market are adopting various strategies, such as the launch of innovative products, partnerships & collaborations, and mergers & acquisitions to maintain their market presence.
Leading companies such as Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, and Danaher Corporation have gained significant market share due to their advanced bioprocessing platforms, scalable bioreactor technologies, and end-to-end service offerings. These companies support various applications, including process development, academic research, and clinical manufacturing, helping biopharmaceutical organizations accelerate development timelines.
To learn more about this report,Download Free Sample Report
Lonza Group, Eppendorf AG, and Miltenyi Biotec also play a critical role in shaping the market by focusing on high-quality, user-centric solutions tailored for cell and gene therapy, regenerative medicine, and vaccine production. Their integrated offerings often include compact, modular systems and automation tools designed to meet the evolving demands of both research and commercial environments.
With the ongoing shift toward precision medicine, decentralized manufacturing, and sustainable bioprocessing, companies that can deliver intelligent, scalable, and cost-effective solutions are well-positioned to lead. A synergy of technological advancement, regulatory alignment, and responsiveness to the fast-paced needs of modern bioproduction will shape the future of the small-scale bioreactors industry.
Key Small-scale Bioreactors Companies
The following key companies have been profiled for this study on the small- scale bioreactors market.
-
Sartorius AG
-
Thermo Fisher Scientific Inc.
-
Merck KGaA
-
Danaher Corporation
-
Lonza Group
-
Eppendorf AG
-
Miltenyi Biotec
-
Getinge AB
-
DONALDSON ITALIA S.R.L. (Solaris Biotechnology Srl)
-
Infors AG
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Global Players (Sartorius AG; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corporation; Lonza Group; Eppendorf AG)
- Expanding small-scale bioreactor portfolios across reusable and single-use systems; developing advanced parallel bioreactor platforms; strengthening automation, process monitoring, and digital integration; and expanding global distribution networks.
- Broad product portfolios, strong global presence, established customer relationships, advanced bioprocessing technologies, and extensive R&D capabilities.
- High equipment costs, complex product offerings, competition from specialized manufacturers, and varying customer requirements across capacity ranges.
Specialized and Emerging Players (Miltenyi Biotec; Getinge AB; Donaldson Italia S.r.l. (Solaris Biotechnology Srl); Infors AG)
- Strengthening specialized bioreactor offerings, developing application-specific systems, improving process control and automation capabilities, and expanding presence across research and biopharmaceutical applications.
- Specialized engineering expertise, differentiated product configurations, application-focused solutions, and established expertise in bioprocessing equipment.
- Relatively narrower product portfolios in certain capacity ranges, comparatively limited global reach, and competition from diversified bioprocessing equipment manufacturers.
Recent Developments
-
In April 2025, Thermo Fisher Scientific introduced the 5L DynaDrive Single-Use Bioreactor, a benchtop solution to improve scalability and efficiency in bioprocess development. Designed for use by large biopharmaceutical companies, CDMOs, and emerging biotech firms, the system enables seamless scale-up from 1 to 5,000 liters, facilitating cost-effective progression from laboratories to commercial manufacturing. The DynaDrive bioreactor offers a 27% boost in productivity over conventional glass systems. It incorporates sustainable features, including biobased Aegis films and BioTitan Retention Devices, to reduce environmental impact and minimize product loss.
-
In November 2024, Lonza completed its first GMP-compliant product batch at its mammalian manufacturing facility in Portsmouth, New Hampshire. Featuring a 2,000L single-use bioreactor system, the facility is designed to support small- to mid-scale biologics production, particularly for treatments targeting rare diseases. This new capacity complements the site's existing 6,000L and 20,000L production capabilities, strengthening Lonza's ability to meet the increasing demand for biologics during early commercial launches. The facility integrates cutting-edge process analytical technologies and streamlined production workflows to ensure a dependable and efficient path to market for a wide range of molecule types.
-
In November 2021, Donaldson Company acquired Solaris Biotechnology Srl, a bioprocessing equipment manufacturer in Porto Mantovano, Italy. This acquisition strengthens Donaldson’s position in the life sciences sector, with a focus on biotechnology, food and beverage, and related industries. Solaris offers a broad range of products, from benchtop systems for R&D to pilot and commercial-scale manufacturing equipment.
Small-scale Bioreactors Market Report Scope
Report Attribute
Details
Market size in 2025
USD 826.6 million
Estimated market size in 2026
USD 877.8 million
Projected market size by 2033
USD 1,497.2 million
Growth rate
CAGR of 7.9% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, capacity, application, end-user, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Denmark, Sweden, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, Saudi Arabia, South Africa, UAE, Kuwait
Key companies profiled
Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group, Eppendorf AG, Miltenyi Biotec, Getinge AB, DONALDSON ITALIA S.R.L. (Solaris Biotechnology Srl), Infors AG
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Small-scale Bioreactors Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global small-scale bioreactors market on the basis of product, capacity, application, end-user, and region:
-
Product Outlook (Revenue, USD Million, 2021 - 2033)
-
Reusable Bioreactors
-
Stainless Steel Bioreactors
-
Glass Bioreactors
-
-
Single-use Bioreactors
-
-
Capacity Outlook (Revenue, USD Million, 2021 - 2033)
-
5 ML -100 ML
-
100 ML-250 ML
-
250 ML -500 ML
-
500 ML-1 L
-
1L-3L
-
3L-5L
-
5L-10L
-
-
Application Outlook (Revenue, USD Million, 2021 - 2033)
-
Process Development
-
Process Optimization
-
Screening
-
Process Characterization
-
Scale-up / Scale-down
-
-
End-User Outlook (Revenue, USD Million, 2021 - 2033)
-
Pharmaceutical & Biopharmaceutical Companies
-
CROs & CMOs
-
Academic & Research Institutes
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The small-scale bioreactors market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each small-scale bioreactors segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Product
Revenue Capture Definition
Reusable Bioreactors
Revenue generated from reusable small-scale bioreactor systems designed for repeated use across multiple cultivation and bioprocessing cycles. This includes systems manufactured using glass and stainless steel, along with associated vessels and integrated components.
Single-use Bioreactors
Revenue generated from small-scale bioreactor systems incorporating disposable, single-use vessels or cultivation containers, typically made from specialized polymer materials. These systems are used for cell culture, microbial fermentation, screening, and process development, reducing cleaning and sterilization requirements between batches.
Capacity
Revenue Capture Definition
5-100 mL
Revenue generated from small-scale bioreactor systems with working capacities ranging from 5 mL to 100 mL, primarily used for high-throughput experimentation, early-stage cell culture studies, and parallel screening applications.
100-250 mL
This segment captures revenue from bioreactors with capacities ranging from 100 mL to 250 mL, used for cell line evaluation, media optimization, screening, and preliminary process development studies.
250-500 mL
Market value in this category stems from small-scale bioreactors with capacities ranging from 250 mL to 500 mL, used for process optimization, characterization, and evaluating cultivation parameters under controlled conditions.
500 mL-1 L
Revenue generated from bioreactor systems with capacities ranging from 500 mL to 1 L, primarily used for process development, experimental validation, and evaluating bioprocess performance before larger-scale operations.
1-3 L
This segment captures revenue from bioreactors with capacities ranging from 1 L to 3 L, commonly used for process development, optimization, and scale-up studies involving biologics, microbial products, and advanced therapeutics.
3-5 L
Market value in this category stems from bioreactor systems with capacities ranging from 3 L to 5 L, used for process characterization, cultivation studies, and evaluating process scalability under controlled conditions.
5-10 L
Revenue generated from bioreactors with capacities ranging from 5 L to 10 L, primarily used for advanced process development, scale-up validation, and pilot-scale cultivation studies before commercial manufacturing.
Application
Revenue Capture Definition
Process Development
Revenue generated from small-scale bioreactors used to establish and develop bioprocesses, including initial evaluation of cell culture conditions, media formulations, feeding strategies, and operating parameters for biologics and other biopharmaceutical products.
Process Optimization
This segment captures revenue from small-scale bioreactors used to optimize existing bioprocesses by evaluating critical process parameters, including temperature, pH, dissolved oxygen, agitation, and nutrient availability to improve productivity and product quality.
Screening
Market value in this category stems from small-scale bioreactors used for high-throughput screening of cell lines, microbial strains, media formulations, and process conditions to identify suitable candidates and operating parameters.
Process Characterization
Revenue generated from small-scale bioreactors used to characterize bioprocess performance, evaluate process variability, and understand the relationship between critical process parameters and critical quality attributes under controlled experimental conditions.
Scale-up / Scale-down
This segment captures revenue from small-scale bioreactors used to simulate larger-scale manufacturing conditions or evaluate the transferability of processes across different working volumes, supporting scale-up development and scale-down model validation.
End User
Revenue Capture Definition
Pharmaceutical & Biopharmaceutical Companies
Revenue generated from small-scale bioreactors purchased or used directly by pharmaceutical and biopharmaceutical companies for biologics development, cell culture research, process development, optimization, screening, and manufacturing process scale-up studies.
CROs & CMOs
This segment captures revenue from small-scale bioreactors purchased or used by contract research organizations (CROs) and contract manufacturing organizations (CMOs) to provide outsourced bioprocess development, process optimization, screening, and characterization services to pharmaceutical and biotechnology clients.
Academic & Research Institutes
Market value in this category stems from small-scale bioreactors purchased or used by universities, academic laboratories, and research institutions for fundamental research, microbial cultivation, cell culture studies, bioprocess development, and experimental investigations.
Estimation Model
Step
Approach / Method
Description
1
Top-Down Commodity Flow Analysis
Aggregated revenues of key small-scale bioreactor providers across reusable and single-use systems, including SUBs bioreactors, stainless steel bioreactors, and related accessories. Estimates were validated using company reports, investor presentations, industry databases, publications, and primary interviews.
2
Parent Market & Penetration-Based Analysis
Derived the global market size from the broader bioreactor and bioprocessing markets. Allocation was based on small-scale system adoption, biopharmaceutical R&D investments, process development activities, and demand for laboratory-scale bioprocessing across regions.
3
Primary Research Industry Expert & Stakeholder Interviews
Conducted interviews with bioreactor manufacturers, pharmaceutical and biotechnology companies, CROs, CDMOs, process engineers, and industry experts to validate pricing, capacity preferences, adoption patterns, and competitive dynamics.
4
Validation Data Triangulation and Cross-Verification
Market estimates were validated through secondary research, primary interviews, company-level revenue assessments, product shipment data, and end-user adoption trends across pharmaceutical companies, CROs, CDMOs, and academic institutions.
5
Forecasting Trend-Based Market Projection Model
Forecasts were developed using trends in biologics R&D, increasing demand for process development and optimization, adoption of single-use technologies, automation, and expansion of cell and gene therapy research, supported by trend analysis and scenario-based modeling.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Small-Scale Bioreactor Capacity & Application Assessment
Comparative assessment of demand across capacity ranges (5-100 mL to 5-10 L) and applications, including process development, screening, process optimization, characterization, and scale-up/down studies.
Helps clients identify high-demand capacity ranges, understand application-specific requirements, and prioritize product development opportunities.
Global Company Market Share Analysis
Assessment of the global market shares of key small-scale bioreactor manufacturers based on estimated 2025 revenue, product portfolios, capacity offerings, and competitive positioning.
Helps clients understand the competitive landscape, benchmark key market participants, evaluate competitor positioning, and identify opportunities to strengthen their global market presence.
Small-Scale Bioreactor Technology & Product Preference Assessment
Assessment of customer preferences for reusable and single-use bioreactors, including stirred-tank configurations, parallel bioreactor systems, automation, and process monitoring capabilities.
Helps clients understand technology adoption trends, evaluate product differentiation opportunities, and align offerings with evolving end-user requirements.
Frequently Asked Questions About This Report
Asia Pacific is the fastest-growing region over the forecast period.
The single-use bioreactors segment held the highest market share of 55.0% in 2025.
The 1L-3L segment held the highest market share of 26.4% in 2025.
The pharmaceutical & biopharmaceutical companies segment held the highest market share of 42.8% in 2025.
North America dominated with a 37.3% revenue share in 2025.
Some key players operating in the small-scale bioreactors market include Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher, LAMBDA Instruments GmbH, Eppendorf AG, Solida Biotech GmBH, Getinge AB, DONALDSON ITALIA S.R.L. (Solaris Biotechnology Srl), Infors AG
Key factors that are driving the market growth include increasing investments for biotech based research along with increasing demand for single-use bioreactors
The global small-scale bioreactors market size was valued at USD 826.6 million in 2025 and is estimated at USD 877.8 million for 2026.
The global small-scale bioreactors market is expected to grow at a CAGR of 7.9% from 2026 to 2033, reaching USD 1,497.2 million by 2033.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.